http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2602465-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate | 2005-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86429ff7833df4076e456c26693831ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1815f4cc041eaa4b9f0d397d38fb060b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb71b7bd7a1e65c03d8e17325d8a8d1b |
| publicationDate | 2017-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2602465-T3 |
| titleOfInvention | Combinations for the treatment of diseases that involve cell proliferation |
| abstract | A pharmaceutical composition, comprising effective amounts of: (i) (A compound 1 of formula (I): ** Formula ** wherein the abbreviations X1, X2, X3, X4 and X5 used in the Table mean in each case a binding to the position in the general formula shown in the Table instead of the corresponding groups R1, R2, R3, R4 and L-R5, optionally in the form of their tautomers, racemates, enantiomers, diastereomers and mixtures thereof and optionally in the form of the pharmacologically acceptable acid, solvate, hydrate or polymorphic addition salts thereof; and (ii) at least one additional therapeutic agent 2 selected from the group consisting of vatalanib, gefitinib, erlotinib, iressa, tarceva, herceptin, atrasentan, rituximab, cetuximab, Avastin tm (bevacizumab), IMC-1C11, erbitux (C-225), DC-101, EMD-72000, vitaxin, imatinib, VEGFtrap, melphalan, cyclophosphamide, an oxazaphosphine, doxorubicamine (docloorubicamine) adriamycin), doxorubic ina liposomal (doxil), epirubicin, idarubicin, mitoxantrone, amsacrine, dactinomycin, distamycin, netropsin, pibenzimol, mitomycin, CC-1065, duocarmycin, mitramycin, chromomycin, olivomycin, propamidine, stilbamidine, an antramycin, an antramreacin phleomycin a bleomycin, liblomicina, navelbine, vinblastine, vincristine, vindesine, vinorelbine, colchicine, maytansine, fomopsina, dolastatin, etoposide, teniposide, combretastatin, anfetinilo, procarbazine, bortezomib, asparaginase, pegylated asparaginase (pegaspargase), inhibitor timidinafosforilasa, estramustine (T-66), megestrol, flutamide, casodex, anandron, cyproterone acetate, aminoglutethimide, anastrozole, formestan, letrozole, leuprorelin, buserelin, goserelin or triptorelin, tamoxifen, droloxifene, trioxifene, raloxifenoid, zindoxadiene, zindoxadiene, zindoxadiene, zindoxadiene finasteride, ketoconazole, leuprolide, prednisone, prednisolone, methylprednisolone, dexamethasone, budenoside, fluoc ortholone or triamcinolone, interferon, interferon β, IL-10, IL-12, etanercept, thalidomide, revimid mitomycin C, misonidazole, NLP-1 or NLA-1, nitromine, an anti-CD3 or anti-CD25 antibody, minodronic acid, Zoledronic acid monohydrate, ibandronate hydrated sodium, disodium clodronate, metronidazole, misonidazole, benznidazole, nimorazole, RSU-1069, SR-4233, bromodeoxyuridine, iododeoxyuridine, porphimer, photofrine, merocyanine 540 (MC-540, acetylpurine, acetylpurine acid, mesalazine, ibuprofen, naproxen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozine, pranoprofen, miroprofen, thioxaprofen, suprofen, alminoprofen, thiaxaprofenocoenomethyl, toluprocophene, zupotophenochlorine, zuprocophene, zuprobenzene, zuprocophene, zuprobenzene, zuproenophenophenone , fenclofenac, alclofenac, bromfenac, ibufenac, aceclofenac, acemetacin, fentiazac, clidanac, etodolac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, acid Nifluminic, tolfenamic acid, diflunisal, flufenisal, piroxicam, tenoxicam, lornoxicam, nimesulide, meloxicam, celecoxib, rofecoxib, apolizumab, 1D09C3, TIMP-1, TIMP-2, Zinc, tetrathomolibdate, squattata, quantalatin, squattata, quantalatin, quantalatin, quantalatin, quantalatin, quantalatin, squat Neovastat, bicalutamide, abarelix, oregovomab, mitumomab, TLK-286, alemtuzumab, ibritumomab, temozolomide, denileukin diftitox, aldesleukin, dacarbazine, floxuridine, plicamycin, mitotane, pipobroman, or optionally, in combination with pharmaceutically, in combination with pharmaceutically, in combination with pharmaceutical acceptable, and optionally intended for co-treatment with radiotherapy or radio-immunotherapy, in the form of a combined preparation for simultaneous, separate or sequential use in the treatment of diseases involving cell proliferation, cell migration or apoptosis of cancer cells, or angiogenesis . |
| priorityDate | 2004-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 919.